# US 2008/0187530 A1 · Novel Agents and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187530 A1
- Document ID: US20080187530A1
- Status: Published application
- Kind: A1
- Application number: 11/793,708
- Filed: 2005-12-16
- Published: 2008-08-07
- Earliest claimed: 2004-12-22
- Assignees: Lipopeptide AB
- Inventors: Mona Stahle; Johan Heilborn; Margareta Frohm Nilsson; Gunther Weber
- Web page: https://patentgrep.com/patent/US20080187530A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- C07K 16/3092: {against tumour-associated mucins}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides agents for inhibiting the proliferation of cancer cells, wherein the agent inhibits the biological activity of hCAP18/LL-37. In a preferred embodiment, the agent alters the transcription, translation and/or binding properties of hCAP18/LL-37. Preferably, the agent is selected from the group consisting of short interfering RNA (siRNA) molecules, antisense oligonucleotides and compounds with binding affinity for hCAP18/LL-37. The invention further provides methods for inhibiting the proliferation of cancer cells in a patient, as well as methods and kits for diagnosing cancer.

## Claims

### Claim 1

An agent for inhibiting the proliferation of breast cancer cells, wherein the agent is capable of inhibiting in vivo the biological activity of hCAP18/LL-37.

### Claim 2 (depends on 1)

An agent according to claim 1 wherein the biological activity of hCAP18/LL-37 comprises the proliferation of epithelial cells.

### Claim 3

An agent according to claim wherein the agent inhibits the biological activity of hCAP18/LL-37 by altering the transcription, translation and/or binding properties of hCAP18/LL-37.

### Claim 4 (depends on 1)

An agent according to claim 1, wherein the agent is an inhibitor of the transcription of hCAP18/LL-37.

### Claim 5 (depends on 1)

An agent according to claim 1, wherein the agent is an inhibitor of the translation of hCAP18/LL-37.

### Claim 6 (depends on 1)

An agent according to claim 1, wherein the agent is an inhibitor of the binding properties of hCAP18/LL-37.

### Claim 7 (depends on 1)

An agent according to claim 1 wherein the agent is an hCAP18/LL-37 receptor antagonist.

### Claim 8 (depends on 7)

An agent according to claim 7 wherein the hCAP18/LL-37 receptor is FPRL1.

### Claim 9 (depends on 1)

An agent according to claim 1 wherein the agent is capable of inhibiting the biological activity of hCAP18/LL-37 in cancer cells selectively.

### Claim 10 (depends on 1)

An agent according to claim 1 wherein the agent is capable of inhibiting the biological activity of hCAP18/LL-37 by 50% or more compared to the biological activity of hCAP18/LL-37 in cancer cells which have not been exposed to the agent.

### Claim 11 (depends on 1)

An agent according to claim 1 wherein the agent is selected from the group consisting of short interfering RNA (siRNA) molecules, antisense oligonueleotides, compounds with binding affinity for hCAP18/LL-37 and small inhibitor compounds.

### Claim 12 (depends on 1)

An agent according to claim 1 wherein the agent is a short interfering RNA (siRNA) molecule.

### Claim 13 (depends on 12)

An agent according to claim 12 wherein the siRNA molecule comprises a fragment of the nucleotide sequence of SEQ ID NO:1, or a variant thereof.

### Claim 14 (depends on 12)

An agent according to claim 12 wherein the siRNA molecule is 19 to 23 nucleotides in length.

### Claim 15 (depends on 1)

An agent according to claim 1 wherein the agent is an antisense oligonucleotide.

### Claim 16 (depends on 15)

An agent according to claim 15 wherein the antisense oligonucleotide comprises a fragment of the nucleotide of SEQ ID NO:1, or a variant thereof.

### Claim 17 (depends on 15)

An agent according to claim 15 wherein the antisense oligonucleotide is 15 to 35 nucleotides in length.

### Claim 18 (depends on 1)

An agent according to claim 1 wherein the agent is a compound with binding affinity for hCAP18/LL-37.

### Claim 19 (depends on 1)

An agent according to claim 1 wherein the agent is a small inhibitor compound.

### Claim 20 (depends on 18)

An agent according to claim 18 wherein the compound is a polypeptide.

### Claim 21 (depends on 20)

An agent according to claim 20 wherein the polypeptide is an antibody or an antigen-binding fragment thereof.

### Claim 22 (depends on 21)

An agent according to claim 21 wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of Fv fragments, Fab-like fragments, single variable domains and domain antibodies.

### Claim 23 (depends on 21)

An agent according to claim 21 wherein the antibody or an antigenbinding fragment thereof is humanised.

### Claim 24 (depends on 18)

An agent according to claim 18 wherein the compound has ligandbinding capacity for hCAP18/LL-37.

### Claim 25 (depends on 1)

An agent according to claim 1 wherein the agent is capable of being selectively delivered to or selectively activated by the cancer cells.

### Claim 26 (depends on 25)

An agent according to claim 25 wherein the agent comprises a target cell specific portion.

### Claim 27 (depends on 26)

An agent according to claim 26 wherein the target cell specific portion is an antibody or antigen-binding fragment thereof.

### Claim 28 (depends on 27)

An agent according to claim 27 wherein the antibody or antigen-binding fragment thereof is humanised.

### Claim 29 (depends on 27)

An agent according to claim 27 wherein the antibody or antigenbinding fragment thereof has specificity for an antigen expressed on the surface of the cancer cell.

### Claim 30 (depends on 29)

An agent according to claim 29 wherein the antigen expressed on the surface of the cancer cell is selected from the group consisting of C46, 85A12, H17E2, NR-LU-10, HMFG1, SM-3(IgG1), W14, L6 (IgG2a), 1F5 (IgG2a), alphafoetoprotein, Ca-125, prostate specific antigen and members of the epidermal growth factor receptor family.

### Claim 31 (depends on 25)

An agent according to claim 25 wherein the agent is a prodrug selectively activated by the cancer cell.

### Claim 32 (depends on 1)

An agent according to claim 1 wherein the breast cancer cells are Elston grade III cells.

### Claim 33 (depends on 1)

An agent according to claim 1 wherein the breast cancer cells are metastatic.

### Claim 34 (depends on 1)

A pharmaceutical composition comprising an agent according to claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 35 (depends on 34)

A pharmaceutical composition according to claim 34 suitable for parenteral administration.

### Claim 36 (depends on 34)

A pharmaceutical composition according to claim 34 wherein the formulation is capable of targeted delivery of the agents to the cancer cells.

### Claim 37 (depends on 1)

A method for inhibiting the proliferation of cancer cells in a patient, the method comprising administering to the patient an agent according to claim 1 or a pharmaceutical formulation wherein the cancer cells are breast cancer cells.

### Claim 38 (depends on 37)

A method according to claim 37 wherein the patient is human.

### Claim 39 (depends on 37)

A method according to claim 37 wherein the agent is selectively delivered to or selectively activated by the cancer cells.

### Claim 40 (depends on 1)

An agent according to claim 1 for use in medicine.

### Claim 41 (depends on 40)

An agent according to claim 40 for use in the treatment of breast cancer.

### Claim 42 (depends on 1)

Use of an agent according to claim 1 in the preparation of a medicament for inhibiting the proliferation of cancer cells, wherein the cancer cells are breast cancer cells.

### Claim 43 (depends on 37)

A method according to claim 37 wherein the breast cancer cells are Elston grade III cells.

### Claim 44 (depends on 43)

A method or use according to claim 43 wherein the breast cancer cells are metastatic.

### Claim 45

A method for detecting breast cancer cells in a patient, the method comprising the following steps:
(a) providing a sample of breast cells from a patient to be tested;
(b) measuring the amount of hCAP18/LL-37 produced by the cells; and
(c) comparing the amount of hCAP18/LL-37 measured in step (b) with the amount of hCAP18/LL-37 produced by healthy breast cells
wherein elevated levels of hCAP18/LL-37 production in the sample of cells from a patient compared to the levels in healthy cells indicates that the cells are cancer cells.

### Claim 46 (depends on 45)

A method according to claim 45 wherein the sample of cells in step (a) are from a tumour or from tissue suspected of being a tumour.

### Claim 47 (depends on 45)

A method according to claim 45 wherein step (b) comprises contacting the sample of cells with an agent that binds to hCAP18/LL-37 and then detecting the amount of hCAP18/LL-37 bound thereto.

### Claim 48 (depends on 47)

A method according to claim 47 wherein the agent that, binds to hCAP18/LL-37 is an antibody or antigen-binding fragment thereof

### Claim 49 (depends on 47)

A method according to claim 47 wherein step (b) comprises (i) contacting the cells with an agent that binds to hCAP18/LL-37 and (ii) detecting the amount of the hCAP18/LL-37 that binds to the agent using an antibody or antigen-binding fragment thereof.

### Claim 50 (depends on 47)

A method according to claim 47 wherein step (b) is performed by ELISA.

### Claim 51 (depends on 45)

A method according to claim 45 wherein step (b) comprises measuring the amount of hCAP18/LL-37 mRNA in the cells.

### Claim 52 (depends on 51)

A method according to claim 51 wherein step (b) is performed by Southern blot or RT-PCR.

### Claim 53 (depends on 45)

A method for monitoring the progression of cancer in a patient, the method comprising:
(a) providing a sample of cells collected from the patient at a first time point and detecting cancer cells therein using a method according to claim 45;
(b) providing a sample of cells collected from the patient at a second time point and detecting cancer cells therein using a method according to claim 45; and
(c) comparing the number of cancer cells measured in steps (a) and (b)
wherein an increased number of cancer cells measured in step (b) compared to step (a) is indicative of a progression in the cancer.

### Claim 54 (depends on 45)

A diagnostic kit for performing a method according to claim 45 comprising an agent that binds to hCAP18/LL-37 or to mRNA encoding the same.

### Claim 55 (depends on 54)

A diagnostic kit according to claim 54 comprising an antibody or antigenbinding fragment thereof capable of binding to hCAP18/LL-37.

### Claim 56 (depends on 55)

A diagnostic kit according to claim 55 further comprising a secondary antibody capable of binding to the antibody or antigen-binding fragment thereof which is capable of binding to hCAP18/LL-37.

### Claim 57 (depends on 54)

A diagnostic kit according to claim 54 wherein the agent is an oligonucleotide capable of hybridising selectively to hCAP18ILL-37 mR,′A.

### Claim 58 (depends on 57)

A diagnostic kit according to claim 57 wherein the oligonucleotide comprises or consists of a fragment of the nucleotide sequence of SEQ ID NO: I, or a variant thereof.

### Claim 59 (depends on 58)

A diagnostic kit according to claim 58 wherein the oligonucleotide comprises a detectable moiety.

### Claim 60 (depends on 59)

A diagnostic kit according to claim 59 wherein the detectable moiety is selected from the group consisting of radioisotopes, radionuclides, fluorescent labels, enzymatic labels, chemiluminescent, biotinyl groups, and predetermined polypeptide epitopes recognised by a secondary reporter.

### Claim at position 61

61-68. (canceled)
